Physician profile
Eric James Lake
NPI 1710919139
$1,093.32
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $165 · 2021: $28.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $248.11 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.77 | 2019-2021 | |
| Pacira Therapeutics, INC. | $95.00 | 2019-2020 | |
| Depuy Synthes Sales INC. | $71.01 | 2019-2020 | |
| Nevro Corp. | $68.37 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $64.55 | 2019 | |
| Sanofi-Aventis U.S. LLC | $64.32 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $59.77 | 2019 | |
| Radius Health, INC. | $58.60 | 2019 | |
| Zyla Life Sciences, INC. | $51.70 | 2019 | |
| Electronic Waveform Lab, INC. | $42.59 | 2019 | |
| Arteriocyte Medical Systems, INC. | $34.83 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.58 | 2019-2020 | |
| Abbott Laboratories | $25.99 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.39 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.34 | 2019 | |
| Fidia Pharma USA INC. | $16.38 | 2019 | |
| Pfizer INC. | $11.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.